



Cleveland Cord Blood Center Leadership

Marcie Finney, Executive Director

Marcie Finney is the Executive Director of the Cleveland Cord Blood Center. With an extensive background in the field of cord blood, she spent over 10 years at Case Western Reserve University where she participated in cord blood research. As Executive Director, her responsibilities include strategic planning, finance, administration and quality product development. She is active in the cellular therapy community, sharing knowledge and experiences in cord blood banking research and cellular therapy in presentations throughout the U.S. and globally. Prior to her current role, she served as the organization's Director of Hospital Relations where she headed the education and training of collection coordinators and medical staff at hospital collection sites. She received a Master of Science in Chemistry and an MBA from Case Western Reserve University, and a Bachelor of Science in Chemistry from Slippery Rock University. Finney serves on the Board of Directors for the Cord Blood Association, one of the industry's foremost organizations. She is a member of the Advisory Board for Gamida, a cell therapy company that is pioneering new standards of care for patients with blood cancers and other blood diseases. Finney also serves on the Board of Directors for the Goodwill Industries of Greater Cleveland and East Central Ohio.

Mary J. Laughlin, M.D., Founder and Medical Director

Mary J. Laughlin, M.D., is the Founder and Medical Director of the Cleveland Cord Blood Center. Dr. Laughlin is an internationally recognized hematology expert in allogeneic cord blood transplantation for adults and pediatric patients with leukemia and other hematological malignancies, and hemoglobinopathies including sickle cell disease. Dr. Laughlin, who has been a practicing physician in bone marrow and stem cell transplantation since 1992, performed one of the world's first successful umbilical cord blood transplants in an adult leukemia patient in 1995 and conducted studies over the ensuing 25 years to establish cord blood as a new standard in the field. She previously served as President for the International Society for Cellular Therapeutics. She received her medical degree from SUNY in Buffalo, New York, and a Bachelor of Science in Nursing from the University of Rochester.

Wouter Van't Hof, Ph.D., Director, Cord Blood Bank & CEO, Cleveland Cell Therapy Incubator

Wouter Van't Hof has his Ph.D. in Cell Biology with over 25 years of biotech experience in translational research and development of adult stem cell therapies, including bone marrow stromal cells (MSC) and HPC, Cord Blood. He is accomplished in technology invention and transfer, product characterization, process development and scale up. His experience includes the management of projects with cross-functional teams in academia, biotech, and pharmaceuticals both in the U.S. and abroad. Van't Hof was the Cleveland Cord Blood Center lead in acquiring FDA biologics license approval for the HPC, Cord Blood product CLEVECORD™ and oversees the organization's CMC, Process Validation, Aseptic Processing, and GMP compliance. From 2002 – 2013, he was Director at Athersys (Cleveland, OH) and was responsible for technology transfer, product and process development, preclinical safety, regulatory discussion, clinical study design and management. Van't Hof contributed to the CMC and Pharm/Tox sections of four approved IND applications for cell therapies.